These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30138677)

  • 21. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
    Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
    Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel germline gain-of-function variant in PIK3CD.
    Rae W; Gao Y; Ward D; Mattocks CJ; Eren E; Williams AP
    Clin Immunol; 2017 Aug; 181():29-31. PubMed ID: 28578023
    [No Abstract]   [Full Text] [Related]  

  • 23. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gain of Function Mutations of PIK3CD as a Cause of Primary Sclerosing Cholangitis.
    Hartman HN; Niemela J; Hintermeyer MK; Garofalo M; Stoddard J; Verbsky JW; Rosenzweig SD; Routes JM
    J Clin Immunol; 2015 Jan; 35(1):11-4. PubMed ID: 25352054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
    Michalovich D; Nejentsev S
    Front Immunol; 2018; 9():369. PubMed ID: 29535736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.
    Zhao P; Huang J; Fu H; Xu J; Li T; Zhang X; Meng Q; Zhang L; Tan L; Zhang W; Chen H; Lu X; Ding Y; He X
    Pediatr Rheumatol Online J; 2024 Jan; 22(1):24. PubMed ID: 38287413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Treatment of Activated PI3Kδ Syndrome.
    Coulter TI; Cant AJ
    Front Immunol; 2018; 9():2043. PubMed ID: 30245694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunodeficiency due to a novel variant in PIK3CD: a case report.
    Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. E1021K Homozygous Mutation in PIK3CD Leads to Activated PI3K-Delta Syndrome 1.
    Wang Y; Chen X; Yang Q; Tang W; Jia Y; Zhou L; An Y; Zhang Z; Tang X; Zhao X
    J Clin Immunol; 2020 Feb; 40(2):378-387. PubMed ID: 31953711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4
    Bier J; Rao G; Payne K; Brigden H; French E; Pelham SJ; Lau A; Lenthall H; Edwards ESJ; Smart JM; Cole TS; Choo S; Joshi AY; Abraham RS; O'Sullivan M; Boztug K; Meyts I; Gray PE; Berglund LJ; Hsu P; Wong M; Holland SM; Notarangelo LD; Uzel G; Ma CS; Brink R; Tangye SG; Deenick EK
    J Allergy Clin Immunol; 2019 Jul; 144(1):236-253. PubMed ID: 30738173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.
    Oh J; Garabedian E; Fuleihan R; Cunningham-Rundles C
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4095-4102. PubMed ID: 34352450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report: Activating
    Lu M; Gu W; Sheng Y; Wang J; Xu X
    Front Immunol; 2021; 12():670312. PubMed ID: 33995405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
    Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
    Front Immunol; 2019; 10():77. PubMed ID: 30891027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
    Li GM; Liu HM; Guan WZ; Xu H; Wu BB; Feng JY; Sun L
    Medicine (Baltimore); 2019 May; 98(18):e15329. PubMed ID: 31045771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea.
    Kang JM; Kim SK; Kim D; Choi SR; Lim YJ; Kim SK; Park BK; Park WS; Kang ES; Ko YH; Choe YH; Lee JW; Kim YJ
    Yonsei Med J; 2020 Jun; 61(6):542-546. PubMed ID: 32469178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
    Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
    Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
    Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
    J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
    Liu H; Tang XL; Liu JR; Li HM; Zhao SY
    Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.